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Background: Cholangiocarcinoma (CC) is one of the fatal malignant neoplasms with poor prognosis. The
traditional chemotherapy has been resistant to CC and does not improve the quality of life. The aim of the present
study is to investigate the potential of chondroitin sulphate (CS)-histamine (HS) block copolymer micelles to
improve the chemotherapeutic efficacy of docetaxel (DTX).
Results: pH-responsive property of CS-HS micelles was utilized to achieve maximum therapeutic efficacy in CC. In
the present study, docetaxel-loaded CS-HS micelles (CSH-DTX) controlled the release of drug in the basic pH while
rapidly released its cargo in the tumor pH (pH 5 and 6.8) possibly due to the breakdown of polymeric micelles. A
nanosize of <150 nm will allow its accumulation in the tumor interstitial spaces via EPR effect. CSH-DTX effectively
killed the cancer kills in a time- and concentration-dependent manner and showed pronounced therapeutic action
than that of free drug at all-time points. CSH-DTX resulted in higher apoptosis of cancer cells with ~30% and ~50
of cells in early apoptosis quadrant when treated with 100 and 1000 ng/ml of equivalent drug. The micellar
formulations showed remarkable effect in controlling the tumor growth and reduced the overall tumor volume
to 1/5th to that of control and half to that of free drug treated group with no sign of drug-related adverse
effects. Immunohistochemical analysis of tumor sections showed that fewer number of Ki-67 cells were present
in CSH-DTX treated group comparing to that of free DTX treated group.
Conclusion: Our data suggests that nanoformulation of DTX could potentially improve the chemotherapy
treatment in cholangiocarcinoma as well as in other malignancies.
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Cholangiocarcinoma (CC) is one of the fatal malignant
neoplasms which arise from epithelium of biliary tract
with high rate of mortality and morbidity [1,2]. The CC
constitutes the 3% of gastrointestinal cancers with ~15%
of overall hepatic cancers [3]. The incidence of CC
among Western countries is 1–2 cases per 100000 per-
sons however East Asia has higher incidence of CC
with ~8 cases per 1000 individuals [4]. The CC has
poor prognosis rate with 5-year survival rate of less
than 10% and has a steady increase in the incidence* Correspondence: wanglei5667@gmail.com
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unless otherwise stated.rate. Approximately, 50% of CC cases are diagnosed at
unresectable stage, as the symptoms are largely unknown
at initial stages [5,6]. At present, surgical resection of CC
tumor is the main treatment option for advanced stage
tumor. However, surgical biliary bypass often causes
serious postoperative complications and increases the
morbidity rate. Additionally, palliative therapies such as
endoscopic stent, radiation therapy, photodynamic
therapy, and chemotherapy are employed to treat the
CC [7]. Among all, chemotherapy is regarded as the
adjuvant or main alternative treatment to CC, however
traditional chemotherapy is reported to be resistant to
CC and does not improve the quality of life [8,9].
Therefore, we need an effective therapeutic strategy
that can overcome the limitation of conventionals is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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effect in CC.
Nanotechnology-based drug delivery system has been
reported to improve the pharmacological and anticancer
property of chemotherapeutic drugs [10]. Specifically,
fenestrated endothelium and heavy blood flow will allow
the nanoparticles to be taken by the liver. This process
can be accelerated by enhanced permeability and
retention effect (EPR) that will allow the preferential
accumulation or passive targeting of nanocarriers to the
leaky vasculature of tumor tissues [11]. Importantly, the
delivery carrier can be made responsive to the local
microenvironment of tumor. The physiological pH of
blood is ~7.2 while the pH of extracellular spaces
around tumor is 6.8 and endolysosomes of cancer cells
was very acidic (pH < 6) [12].
In this regard, block copolymer-based nanosized mi-
celles have attracted significant attention as a promising
delivery system towards cancer therapy [13]. Import-
antly, pH-responsive anticancer drug delivery has many
benefits including high accumulation in tumor tissues,
long blood circulation, limited release in physiological
conditions, and utilizing EPR effect [14]. In the present
study, we have conjugated chondroitin sulphate (CS)
with histamine (HS) to form pH-responsive nanomi-
celles that can enhance the cancer cell killing effect. CS
is a hydrophilic compound with excellent biocompatibility
and biodegradability that made it an excellent choice for
in vivo applications. CS is a vital structural component of
cartilage and connective tissues. CS has been reported to
target cancer cells by binding to the hyaluronic acid recep-
tors expressed on the malignant cells and internalized
actively. HS on the other hand was selected due to its
imidazole ring characteristics [15]. The imidazole ring has
a lone pair of electron on nitrogen that gives it amphoteric
nature to protonate and deprotonate [16].
Docetaxel (DTX), is regarded as one of most effective
chemotherapeutic agent for the cancer treatment. DTX
is a typical microtubule inhibitor that binds with the
microtubule assembly of cancer cells and prohibits its
cell proliferation [17]. DTX is effective against wide
range of cancers including ovarian, breast, head/neck,
lung cancers, and liver cancers. Despite its promising
clinical potential, severe side effects such as bone mar-
row suppression, hypersensitivity reactions, and periph-
eral neuropathy became a major obstacle. Additionally,
poor water solubility and poor bioavailability limited its
clinical application to a great extent [18].
Therefore, main aim of the present study was to load
DTX in CS-HS-based nanomicelles and to utilize the
pH-responsive property to achieve maximum thera-
peutic efficacy in Cholangiocarcinoma. The physico-
chemical characteristics of DTX-loaded CS-HS micelles
(CSH-DTX) were studied in terms of size and releasekinetics. In vitro cytotoxicity assay and apoptosis assay
of free drug and CSH-DTX was studied in QBC939
adenocarcinoma cells. Antitumor efficacy of CSH-DTX
was studied in xenograft nude mice and immunohisto-
chemical studies were performed to evaluate its systemic
performance.
Results and discussion
Cholangiocarcinoma (CC) which arises from epithelium
of bialy tract is one of the fatal malignant neoplasms
with high rate of mortality and morbidity. At present,
conventional chemotherapy is the main treatment
option; however it does not improve the quality of
patient life [2,4]. In this regard, nanotechnological solu-
tions have been reported to improve the therapeutic per-
formance of anticancer drugs. Importantly, a pH-
responsive strategy would increase the accumulation in
tumor tissues, extend blood circulation, and effectively
improve the overall chemotherapeutic efficacy. In the
present study therefore, we have conjugated chondroitin
sulphate (CS) with histamine (HS) to form pH-
responsive nanomicelles that can enhance the cancer cell
killing effect. DTX, a typical microtubule inhibitor has
been selected in this study as an anticancer drug to im-
prove its therapeutic efficacy against CC [18]. Since the
therapeutic application of DTX is hindered by its limited
solubility and systemic toxicity, in the present study,
DTX was loaded into CS-HS conjugate based polymeric
micelles. DTX and CS-HS block copolymer when dis-
solved in water, hydrophobic and hydrophilic part self-
assemble to form a drug loaded micelles (Figure 1). The
so formed micelle (CSH-DTX) has numerous advantages
including pH-sensitive drug via protonation of histidine
residue, high loading efficiency, and potential clinical
translational ability.
Preparation and characterization of DTX-loaded micelles
Physicochemical characterization of polymeric micelles
was carried out in terms of particle size and polydisper-
sity index. The particle size and PDI of CSH-DTX was
measured by dynamic light scattering technique. The
average size of CSH-DTX was observed to be around
110 nm with a fairly uniform dispersion of NP (PDI ~ 0.15)
(Figure 2a). It has been previously reported that micelles
size less than <200 nm could be preferentially accumulated
in the tumor interstitial spaces via enhanced permeability
and retention (EPR) effect [19].
The morphology of CSH-DTX was investigated using
TEM and SEM. The TEM showed a spherical particle
with uniform distribution in the copper grid (Figure 2b).
The size measured by TEM was smaller than observed
via DLS experiment. The discrepancy in size might be
attributed to the hydrodynamic state and dried state
measurement. The morphology was further confirmed
Figure 1 Schematic representation of conjugation of chondroitin sulphate (CS)-histidine (HS) via chemical reactions. Schematic illustration of
self-assembly of docetaxel (DTX) and CS-HS conjugate into polymeric micelles.
Du et al. Journal of Nanobiotechnology  (2015) 13:17 Page 3 of 11by SEM which showed a smooth regular surface, spher-
ical shaped particles (Figure 2c). The size was consistent
with the TEM observation. The drug loading capacity of
DTX was observed to be more than 20% with a high
entrapment of >95%.
In vitro drug release
The release study was carried out in phosphate buffered
saline (PBS, pH 7.4) and acetate buffered saline (ABS,
pH 6.8 and pH 5.0). As shown in Figure 3, release rate
of DTX from CSH-DTX micelles markedly differed with
the change in pH conditions. As expected, acceleratedFigure 2 (a) Typical size distribution analysis of CSH-DTX by dynamic
(TEM) imaging of CSH-DTX (c) scanning electron microscope (SEM) imrelease of DTX was observed at lower pH, while slow re-
lease profile was seen at basic pH conditions. At pH 7.4,
nearly 30% of drug released while 70% of drug released
when the pH of release media was decreased to pH 6.8.
Importantly, release rate was further increased when mi-
celles were incubated in pH 5.0 containing media. Nearly
95% of drug released in pH 5.0 at the end of 72 h of
study period. In all the pH conditions, although slightly
faster release was observed during the initial time points
however no burst release pattern was observed. The mi-
celles exhibited a sustained release profile for DTX. It
could be expected that at physiological pH conditions,light scattering technique (b) transmission electron microscope
aging of CSH-DTX.
Figure 3 Release profile of DTX from CSH-DTX micelles incubated at phosphate buffered saline (pH 7.4) and acetate buffered saline
(pH 6.8 and 5.0). The samples were incubated at 37°C in a rotary shaker (100 rpm). The data are presented as mean ± SD (n = 3). *p < 0.05,
*p < 0.01 is the statistical difference between drug release at pH 5.0, pH 6.5, and pH 7.4.
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highly hydrophobic core leading to low release rate.
However when the pH decreased, accelerated release
was observed due to the protonation of histidine residue.
At lower pH, when the histidine was protonated, imbal-
ance of hydrophilic and hydrophobic force destabilizes
the micelles structure and the drug diffuses in higher
rate [16]. Therefore, CSH micelles could effectively pre-
vent the drug release or drug leakage in physiological
(avoids toxicity) conditions while releases rapidly in
acidic conditions in response to endosomal and lyso-
somal pH.
In vitro cytotoxicity assay
The in vitro cytotoxicity of blank copolymer was studied
in different concentrations against QBC939 CC cells to
evaluate its safety profile. The cells were treated with
concentrations between 0.1 μg/ml to 500 μg/ml. As seen
(Figure 4a), blank polymeric micelles did not exhibit any
significant toxicity in the tested concentration range
after 24 h incubation. Especially, cell viabilities remained
more than >94% at all the concentrations indicating its
excellent safety profile. The least or negligible cytotox-
icity of blank polymer makes it ideal for in vivo cancer
targeting. Followed by which cytotoxicity of free DTX
and CSH-DTX was evaluated in the same cell lines in a
concentration and time dependent manner. As shown in
Figure 4b-d, both free drug as well as drug loaded micel-
lar formulations exhibited a greater cytotoxicity in a
time- and concentration dependent manner. It has to benoted that cytotoxicity of CSH-DTX was more pro-
nounced than that of free drug in all the time points.
IC50 value of individual formulation was calculated to
quantify the cytotoxic effect. The IC50 value of free
DTX remained at 6.45 μg/ml, 2.86 μg/ml, and 0.89 μg/
ml after 24, 48, and 72 h incubation, respectively. On
the other hand, IC50 value of CSH-DTX stood at 2.58
μg/ml, 0.98 μg/ml, and 0.49 μg/ml for the same time
period, respectively. The superior cytotoxicity of CSH-
DTX might be attributed to the pH-driven release of
active therapeutic molecule in the cell cytoplasm. It
could be expected that micelles were internalized into
the cells via endocytosis mechanism where in the drug
released at acidic compartments and travel to site of
action [20]. The cytotoxicity was further confirmed by
cellular morphology. As seen Figure 5a, control cells
were densely packed on the cover slip and of regular
shape, however, DTX treated cells showed signs of apop-
tosis and cells were round and circular. Importantly,
CSH-DTX treated cells were fewer in number (viable
cells were decreased) and scattered with a clear sign of
membrane blebbing and apoptosis.
Apoptosis measurements
Changes in cell morphology resulting in the rounding of
cells are one of the prominent hallmarks of apoptosis.
The apoptosis measurement was carried out by Hoechst
33258 staining. As shown in Figure 5b, untreated cells
did not show any changes in morphology and remained
same after 24 h. Additionally, cells were densely packed
Figure 4 (a) In vitro cytotoxicity of blank polymeric micelles at various concentrations against QBC939 cells (b-d in vitro cytotoxicity of
free DTX and CSH-DTX against QBC939 cells incubated at 24, 48, and 72 h. The cytotoxicity of formulations was evaluated by MTT assay.
The data are presented as mean ± SD (n = 6).
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The free DTX however reduced the number of viable cells
and exhibited typical features of apoptosis. Notably, CSH-
DTX remarkably induced the apoptosis in cancer cells withFigure 5 (a) Cellular morphology of QBC939 cells following incubatio
of the cell apoptosis induced by free DTX and CSH-DTX. The apoptosistypical features of cell death such as chromatic condensa-
tion, membrane blebbing and apoptotic bodies were visible.
Results indicate that the drug loaded micelles could cause
marked condensation and fragmentation of nuclear bodies.n with free DTX and CSH-DTX (b) fluorescence microscopy images
of cells was analysed by Hoechst staining.
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Figure 6 shows the apoptosis analysis (early and late
apoptosis) of QBC939 cells using Annexin V FITC and
PI staining by flow cytometer. In the present study, cells
were treated with 100 ng/ml and 1000 ng/ml of free
DTX and equivalent CSH-DTX formulations and incu-
bated for 24 h. Results indicate that the proportion of
early and late apoptosis cells markedly increased with
the increase in the concentration of chemotherapeutic
drugs. For example, ~10% of cells were in early apop-
tosis quadrant when exposed with 100 ng/ml of free
DTX, while it increased to ~32% for exposure to 1000Figure 6 Flow cytometer analysis of cell apoptosis using annexinV-FITC
a concentration of 100 ng/ml and 1000 ng/ml and incubated for 24 h. **p <ng/ml of drug. As expected, CSH-DTX resulted in
higher apoptosis of cancer cells with ~30% and ~50 of
cells in early apoptosis quadrant for the same concentra-
tions, respectively. Similarly, late apoptosis cells increased
as well in a concentration-dependent manner. The result
was consistent with the cytotoxicity that micellar formula-
tion could remarkably induce the cell apoptosis.
In vivo antitumor efficacy
The antitumor efficacy of free DTX and CSH-DTX was in-
vestigated in QBC939 cells bearing xenograft tumor model.
The mice were intravenously injected with respectiveand PI staining. The cells were exposed with free DTX and CSH-DTX at
0.01 is the statistical difference CSH-DTX and free DTX.
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volume and body weight was noted every alternative day
up to day 20. As shown in Figure 7a, CSH-DTX signifi-
cantly slowed down the growth of tumor in mice models
comparing to that of free DTX and saline treated mice
groups. As expected, blank micelles did not have any effect
on the tumor volume of mice and grew along with control
group. Administration of free DTX although showed some
therapeutic effect however could not inhibit it’s growth
completely. The micellar formulations remarkably sup-
pressed the tumor proliferation by comparison to that of
control and free drug treated animal group. The final tumor
volume of control, blank micelles, free DTX and CSH-DTX
treated groups were ~2500, ~2500, ~1300, and ~600 mm3,
respectively. The main reason behind the superior anti-
tumor efficacy of CSH-DTX was attributed to increased
accumulation of micelles in tumor regions due to EPR
effect and enhanced sensitization of MDR cancer to
DTX. The other reasons might be due to the sustained
release of drug and prolonged blood circulation [21].
Along with therapeutic efficacy of anticancer drug
loaded delivery system, minimization of side effects
remains a big challenge for the successful cancer chemo-
therapy. The change in body weight has been considered
to be an index to evaluate the systemic toxic effects. As
shown in Figure 7b, mice group treated with free DTXFigure 7 In vivo antitumor efficacy study (a) changes in tumor volum
The antitumor study was carried out in QBC939 cells -bearing xenograft m
***p < 0.001 is the statistical difference in the tumor volume between CSHsignificantly reduced its body weight. Approximately,
20% of body weight was reduced in this group indicating
its systemic toxicity. On the other hand, when the same
dose of drug was loaded in polymeric micelles, no body
weight-loss was observed and throughout the study
period the body weight was stable. It should be noted
that the body weight of DTX treated group started
recovering approximately after 8 days (after final injec-
tions). The body weight recovery might be due to the
slow removal of free drug from the vital organs and
clearance from the systemic circulation. The result
therefore indicates that CS-HS based micelles effectively
reduced the drug related side effects while at the same
time improved its therapeutic efficacy as shown by
reduced tumor volume [22].
Histopathological and immunohistochemical analysis
H & E staining was performed to stain the tumor sec-
tions wherein nucleus was stained with hematoxylin
(blue) and extracellular matrix was stained with eosin
(pink). As shown in Figure 8a, control group exhibited
clear cell morphology with excess chromatin and binu-
cleolates. Whereas, free DTX treated group showed
range of necrosis with irregular cellular morphology.
The tissue necrosis further increased for CSH-DTX
treated group with distinct damage to cancer cells. Lacke (b) changes in mice body weight (c) images of tumor sections.
odel and administered thrice at a fixed dose of 5 mg/kg. *p < 0.05,
-DTX and free DTX or CSH-DTX and control group.
Figure 8 (a) histopathology of tumor sections (b) immunohistochemical analysis of tumor cell proliferation (Ki-67) (c) immunohistochemical
analysis of cleaved PARP (apoptosis marker).
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this group.
Immunohistochemical staining of Ki-67 was performed
to evaluate the tumor proliferation ability of individual for-
mulations. As seen (Figure 8b), fewer number of Ki-67
cells were present in CSH-DTX treated cells comparing to
that of free DTX treated group. This further confirms the
enhanced accumulation of drug in the tumor tissues from
micellar formulations and enhanced sensitization of MDR
cancer to DTX.
PARP, a DNA binding enzyme is cleaved by caspase-3
and caspase-7. PARP is an important indicator of apop-
tosis in cancer cells. In this study, level of PARP was con-
sidered as a marker for level of cell apoptosis. As shown in
Figure 8c, cleaved PARP was detected in DTX treated
group, while it was more significant in CSH-DTX treated
group. The enhanced apoptosis in CSH-DTX treated
group was consistent with its excellent antitumor efficacy.
Conclusions
An amphiphilic block copolymer CS-HS-based poly-
meric micelles was prepared and loaded with DTX to
target cholangiocarcinoma. The pH-sensitive behaviour
of histamine in the block copolymer will accelerate the
release of DTX in the tumor region while protects the
therapeutic load in the physiological conditions. In the
present study, CSH-DTX controlled the release of drug
in the basic pH while rapidly released its cargo in the
tumor pH (pH 5 and 6.8) possibly due to the breakdown
of polymeric micelles. A nanosize of <150 nm will allow
its accumulation in the tumor interstitial spaces via EPR
effect. CSH-DTX effectively killed the cancer kills in a
time- and concentration-dependent manner and showed
pronounced therapeutic action than that of free drug at
all-time points. The superior cytotoxicity of CSH-DTX
might be attributed to the pH-driven release of activetherapeutic molecule in the cell cytoplasm. CSH-DTX
resulted in higher apoptosis of cancer cells with ~30%
and ~50 of cells in early apoptosis quadrant when
treated with 100 and 1000 ng/ml of equivalent drug. The
micellar formulations showed remarkable effect in con-
trolling the tumor growth and reduced the overall tumor
volume to 1/5th to that of control and half to that of free
drug treated group with no sign of drug-related adverse
effects. Immunohistochemical analysis of tumor sections
showed that fewer number of Ki-67 cells were present in
CSH-DTX treated cells comparing to that of free DTX
treated group. Our data suggests that nanoformulation
of DTX could potentially improve the chemotherapy
treatment in cholangiocarcinoma as well as in other
malignancies.Materials and methods
Materials
Docetaxel was procured from Sigma-Aldrich (China).
Chondroitin sulphate (CC) was procured from Shanghai
Sangon Biological Engineering Technology & Services Co.
Ltd. (Shanghai, China). Histamine dihydrochloride (HS)
was purchased LSB Biotechnology Inc. (Xi’an, China). 1-(3-
(Dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride
(EDC), N hydroxysuccinimide (NHS) was obtained from
Sigma-Aldrich (China). All other chemicals were of reagent
grade and used without further purification.
Synthesis of chondroitin sulphate (CS)-histamine (HS)
conjugate
Chondroitin sulphate was conjugated with histamine as
reported previously [23]. Briefly, CS was dissolved in 120
ml of phosphate buffered saline (PBS, pH 6.0) main-
tained in a magnetic stirrer for 5 h. Carboxyl group of
CS was activated by the addition of EDC and NHS in
Du et al. Journal of Nanobiotechnology  (2015) 13:17 Page 9 of 11specific quantity one by one. After 30 min, HS was
added and allowed the reaction mixture to proceed for
24 h. The resultant reaction mixture was dialyzed
against phosphate buffer and then the process was
repeated with distilled water. Finally, the product was
lyophilized and stored in dark place.Preparation of docetaxel-loaded polymeric micelles
DTX-loaded CS-b-HS micelles (CSH-DTX) were pre-
pared by a solvent extraction and evaporation method.
Briefly, specific quantity of DTX and CS was dissolved
in 10 ml of dichloromethane. This organic solution
was poured in distilled water and immediately soni-
cated for 5 min to form an O/W emulsion system. The
reaction was allowed to proceed for 24 h in the dark
conditions.Particle size and zeta potential analysis
The mean diameter and surface charge was analyzed
using dynamic light scattering technique by Zetasizer
(Nano-ZS 90, Malvern, Worcestershire, UK). The sam-
ples were measured at 25°C at a fixed angle of 90°C.
Each sample was measure in triplicate.Morphology analysis
The morphological examination of nanoparticles was
carried out using transmission electron microscope
(TEM) (JEM-2010; JEOL, Japan). Nanoparticle disper-
sion was placed on the carbon-coated copper grid and
negatively stained with 2% (w/v) phosphotungstic acids
and air dried. The morphology and surface texture was
further confirmed by scanning electron microscopy
(SEM; FEI Nova NanoSEM 230). The samples were
freeze dried and coated with platinum before the SEM
analysis.Drug-loading and encapsulation efficiency
UV–vis Spectrophotometer was used to calculate loading
capacity and entrapment efficiency of DOX in CSH
micelles was estimated by HPLC technique (LC 1200;
Agilent Technologies, Santa Clara, CA, USA). The mobile
phase consists of acetonitrile and 0.2% trimethylamine
(pH adjusted to 6.4 with phosphoric acid) (48:52, v/v) at
flow rate of 1 mL/min.
The dried solid samples were dissolved in 1 ml of
dichloromethane and sonicated vigorously for 10 min.
This solution was centrifuged (20000 rpm) and super-
natant was collected and injected into HPLC column.
A reverse-phase C18 column (250 mm × 4.6 mm; GL
Science, Tokyo, Japan) was used. The mobile phase was
run at 1 ml/min and detected at 254 nm.DL% ¼ TotalDrug added
Wt: of Polymer þ Wt: of drug inNP
 100%




The drug release study was carried out in various pH
medium. For the release study, freeze dried micelles
were reconstituted in distilled water and 1 ml of it was
placed in dialysis tube and clipped at both the end. The
dialysis tube was placed in a falcon tube with 30 ml of
release media (different pH level). The whole assembly
was placed in a shaking bath at 37°C. At predetermined
time intervals, 1 ml of release sample was collected and
replaced with equal amount of fresh release media. The
amount of drug released in the release media was calcu-
lated from the HPLC technique.
Cell culture
QBC939 cholangiocarcinoma cells were cultured in
RPMI 1640 medium supplemented with 10% fetal bovine
serum (FBS) and 1% penicillin streptomycin mixture.
The cells were maintained in ambient conditions of 37°C
and 5% CO2.
Cytotoxicity assay
The cytotoxicity assay was measured by 3-(4,5-
dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) assay. It is based on the reduction of yellow
MTT by mitochondrial succinate dehydrogenase. MTT
enters the live cells and reduced into insoluble formazan
complex. For this, QBC939 cells were seeded at a dens-
ity of 1 × 104 in a 96-well plate. After 24 h, cells were
exposed to blank polymer, free DTX and CSH-DTX at
different dosing level. The cells were incubated for 24,
48 and 72 h accordingly. At each time point, plate was
removed and treated with 100 μl of MTT solution (5
mg/ml) to each 96-well plate and incubated for 4 h. The
formed formazan crystals were extracted by adding
DMSO and incubated for additional 30 min. The
absorbance of each plate was read at 570 nm using a mi-
croplate reader (Thermo-Fisher, USA). All experiments
were repeated 6 times.
The morphology of cells was observed using a fluorescent
microscope (Leica DM IRBE microscope) and representa-
tive images were selected.
Apoptosis measurement
Hoechst 33258 was used to observe the cell apoptosis.
During cell apoptosis, condensation of chromatin takes
place and DNA gets cleaved into small fragments.
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adenosine-thymidine (AT) part of DNA while in apop-
totic cells, it binds to condensed chromosome. Normal
cells and apoptotic cells were different in their size and
distinct morphology. The drug treated cells were washed
with PBS and stained with Hoechst 33258 for 10 min.
The cells were washed and fixed with 4% paraformalde-
hyde and observed under fluorescence microscope.
Apoptosis analysis by flow cytometry
Apoptosis assay was carried out by flow cytometer. For
this, cells were seeded, incubated for 24 h and treated
with respective formulations (Free DTX and CSH-DTX).
The treated cells were further incubated for 24 h. The
cells were harvested and washed with PBS. The pellets
were resuspended with 100 μl of binding buffer (10 mM
HEPES pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2,
and 1.8 mM CaCl2). The cells were then treated with
FITC-Annexin V and incubated for 20 min and then PI
was added and incubated for additional 10 min. The
cells were analysed for apoptotic cells using FACS
(Becton Dickenson Biosciences, San Jose, CA, USA).
In vivo antitumor efficacy study
In vivo antitumor efficacy study was performed in 7-
week old xenograft nude mice. Briefly, 1 × 106 QBC939
cells (100 μl PBS) were subcutaneously injected into the
right flank of nude mice to establish cholangiocarcinoma
tumor models. The tumours were allowed to grow for
two weeks until it reaches ~150 mm3 size. The mice
were equally divided into 4 groups with 8 mice in each
group; untreated controls, blank micelles, free DTX, and
CSH-DTX at a fixed dose of 5 mg/kg. The samples were
injected thrice via tail vein injection during first two
weeks. The tumor size was measured using Vernier calli-
per for every other alternative day. Tumor volume was
calculated using the formula: volume = 1/2 × Dmax ×
(Dmin)
2. The body weight was measured simultaneously
as an indicator of the systemic toxicity. At the end of the
study period, tumors were surgically removed and fixed
in 10% neutral formalin and embedded in paraffin.
Histopathological and immunohistochemical evaluations
The histopathology of tumor sections was evaluated by
hematoxylin and eosin (H & E) method. The embedded
paraffin tumor sections were cut into 5 μm slices and
stained with H & E staining agent and viewed by micro-
scope (Nikon TE2000U). For immunohistochemical ana-
lysis, rabbit monoclonal primary antibody for cleaved
poly-ADP-ribose polymerase (PARP) (Abcam, Cambridge,
MA, USA) and rat anti-mouse Ki-67 monoclonal antibody
(Maixin Biotechnology Co., Ltd) to quantify Ki-67 expres-
sion was used in the study.Statistical analysis
The experimental data are presented as the mean (standard
deviation (SD). All statistical analyses were performed
using ANOVA or a two-tailed Student’s t-test (GraphPad
Prism 5).
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